Leef Brands (LEEEF) Receivables (2023 - 2026)

Leef Brands (LEEEF) posted Receivables of $2.6 million for Q1 2026, up 65.39% sequentially from $1.6 million in Q4 2025.

Leef Brands (LEEEF) Receivables (2023 - 2026) Analysis & Trends

Leef Brands has reported Receivables for 4 years, with the latest figure at $2.6 million in Q1 2026.

Quarterly Receivables changed N/A year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 million (changed N/A YoY) and the FY2025 annual result came in at $1.6 million, down 33.49% from the prior year.
Receivables advanced to $2.6 million in Q1 2026 per LEEEF's latest filing, from $1.6 million in the prior quarter.
Over five years, Receivables peaked at $2.6 million in Q1 2026 and troughed at $1.6 million in Q4 2025.
A 4-year average of $2.3 million and a median of $2.5 million in 2023 frame the typical range for Receivables.
The sharpest annual moves came in 2024 and 2025: Receivables decreased 5.36% in 2024, then tumbled 33.49% in 2025.
Over 4 years, Receivables stood at $2.5 million in 2023, then fell by 5.36% to $2.4 million in 2024, then sank by 33.49% to $1.6 million in 2025, then jumped by 65.39% to $2.6 million in 2026.
According to Business Quant data, Receivables over the past three periods registered $2.6 million, $1.6 million, and $2.4 million for Q1 2026, Q4 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	3.07 Bn
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	3.49 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	1.57 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	5.84 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	310.30 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	3.67 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	887.00 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	1.15 Bn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	1.08 Bn
10	Leef Brands	59.45 Mn	54.50 Mn	2.41 Mn	2.21 Mn

Download Data